Literature DB >> 9329379

Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation.

V Sundaram1, A N Hanna, L Koneru, H A Newman, J M Falko.   

Abstract

Hypothyroidism is frequently associated with hypercholesterolemia and an increased risk for atherosclerosis, whereas hyperthyroidism is known to precipitate angina or myocardial infarction in patients with underlying coronary heart disease. We have shown previously that L-T4 functions as an antioxidant in vitro and inhibits low density lipoprotein (LDL) oxidation in a dose-dependent fashion. The present study was designed to evaluate the changes in LDL oxidation in subjects with hypothyroidism and hyperthyroidism. Fasting blood samples for LDL oxidation analyses, lipoprotein determinations, and thyroid function tests were collected at baseline and after the patients were rendered euthyroid. The lag phase (mean +/- SEM hours) of the Cu+2-catalyzed LDL oxidation in the hypothyroid state and the subsequent euthyroid states were 4 +/- 0.0.65 and 14 +/- 0.68 h, respectively (P < 0.05). The lag phase during the hyperthyroid phase was 6 +/- 0.55 h, and that during the euthyroid phase was 12 +/- 0.66 h (P < 0.05). The total and LDL cholesterol levels were higher in hypothyroidism than in euthyroidism and were lower in hyperthyroidism than in the euthyroid state. We conclude that LDL has more susceptibility to oxidation in both the hypothyroid and hyperthyroid states. Thus, the enhanced LDL oxidation may play a role in the cardiac disease process in both hypothyroidism and hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329379     DOI: 10.1210/jcem.82.10.4315

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Thyroxine binding to members and non-members of the serine protease inhibitor family.

Authors:  S Benvenga; D Lapa; F Trimarchi
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis.

Authors:  Husniye Baser; Ummugulsum Can; Salih Baser; Fatma Humeyra Yerlikaya; Uysaler Aslan; Bahauddin Taha Hidayetoglu
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

3.  Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?

Authors:  Sridevi V Udupa; Vivian D'Souza; Vinit A Udupa; Poornima A Manjrekar
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 4.  Hypothyroidism and dyslipidemia: modern concepts and approaches.

Authors:  Elizabeth N Pearce
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

5.  Serum paraoxonase 1 activity is decreased in thyroid dysfunction.

Authors:  F Azizi; F Raiszadeh; M Solati; A Etemadi; M Rahmani; M Arabi
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

6.  Altered fructosamine and lipid fractions in subclinical hypothyroidism.

Authors:  Sridevi V Udupa; Poornima A Manjrekar; Vinit A Udupa; D'Souza Vivian
Journal:  J Clin Diagn Res       Date:  2013-01-01

7.  Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort.

Authors:  Elizabeth N Pearce; Peter W F Wilson; Qiong Yang; Ramachandran S Vasan; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

8.  Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women.

Authors:  Ayush Giri; Todd L Edwards; Vicky A LeGrys; Carol E Lorenz; Michele Jonsson Funk; Robin Schectman; Gerardo Heiss; Jennifer G Robinson; Katherine E Hartmann
Journal:  Thyroid       Date:  2014-06-16       Impact factor: 6.568

9.  Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania.

Authors:  Till Ittermann; Robin Haring; Henri Wallaschofski; Sebastian E Baumeister; Matthias Nauck; Marcus Dörr; Markus M Lerch; Markus Lerch; Henriette E Meyer zu Schwabedissen; Dieter Rosskopf; Henry Völzke
Journal:  Thyroid       Date:  2012-05-10       Impact factor: 6.568

10.  Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease.

Authors:  Melpomeni Peppa; Grigoria Betsi; George Dimitriadis
Journal:  J Lipids       Date:  2011-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.